Statement: In the primary trial, all cases of  Enteritis, Vertigo and Cardiac failure occurred in cohort 2.
Primary_evidence: Adverse Events 1:   Total: 52/133 (39.10%)   Thrombocytopenia 2/133 (1.50%)   Anaemia 1/133 (0.75%)   Disseminated intravascular coagulation 0/133 (0.00%)   Atrial thrombosis 1/133 (0.75%)   Cardiac failure 0/133 (0.00%)   Vertigo 0/133 (0.00%)   Vomiting 3/133 (2.26%)   Nausea 1/133 (0.75%)   Colitis 1/133 (0.75%)   Constipation 1/133 (0.75%)   Enteritis 0/133 (0.00%)   Abdominal pain 0/133 (0.00%) Adverse Events 2:   Total: 16/67 (23.88%)   Thrombocytopenia 0/67 (0.00%)   Anaemia 0/67 (0.00%)   Disseminated intravascular coagulation 1/67 (1.49%)   Atrial thrombosis 0/67 (0.00%)   Cardiac failure 1/67 (1.49%)   Vertigo 1/67 (1.49%)   Vomiting 0/67 (0.00%)   Nausea 1/67 (1.49%)   Colitis 0/67 (0.00%)   Constipation 0/67 (0.00%)   Enteritis 1/67 (1.49%)   Abdominal pain 2/67 (2.99%)